Notable Analyst Rating Changes 11/21: (PENN) (THOR) (SKX) Upgraded; (HTWR) (EV) (ICA) Downgraded

November 21, 2012 10:27 AM EST Send to a Friend
Get Alerts PENN Hot Sheet
Price: $14.19 +2.68%

Rating Summary:
    11 Buy, 10 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 3 | Down: 17 | New: 2
Trade PENN Now!
Join SI Premium – FREE
UPGRADES
Lazard Capital upgrades Penn National Gaming (Nasdaq: PENN) from Neutral to Buy.

Wells Fargo boosts Thoratec (Nasdaq: THOR) from Market Perform to Outperform, lifting its valuation range from $34 to $35 to a new range $41 to $42. Click Here for more color.

Susquehanna raises Skechers USA (NYSE: SKX) from Neutral to Positive.

Sandler O’Neill lifts FirstMerit Corporation (Nasdaq: FMER) from Hold to Buy.

For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades

DOWNGRADES
Heartware Int'l (Nasdaq: HTWR) lowered by two firms Wednesday:
  • Wells Fargo from Outperform to Market Perform and lowers its valuation range from $97 to $99 down to a range of $88 to $89. Click Here for more color;

  • UBS from Buy to Neutral.

Citi downgrades Eaton Vance (NYSE: EV) from Neutral to Sell.

UBS reduces Empresas ICA SA (NYSE: ICA) from Buy to Neutral.

Wells Fargo lowers St. Jude Medical (NYSE: STJ) from Outperform to Market Perform and cut its price target range from $49 to $50 to a range of $25 to $36. Click Here for more color.

For daily real-time Downgrades go to http://www.streetinsider.com/downgrades

NEW COVERAGE
LINN Energy (Nasdaq: LINE) started by a handful today:
  • BofA/Merrill Lynch at Neutral and $40 price target;

  • Goldman Sachs at Neutral and $47 target. Click Here for more color;

  • Barclays with an Overweight and $44 target; and

  • UBS at Buy and $43 target.

RBC Capital initiates Infinity Pharmaceutical (Nasdaq: INFI) with an Outperform and $28 price target.

Linn Co, LLC (Nasdaq: LNCO) also started by a slew of analysts Wednesday:
  • Baird at Outperform and $48 target;

  • Goldman Sachs with a Neutral and target of $44. Click Here for more color;

  • Credit Suisse at Neutral and $37.50 target;

  • UBS with a Buy and $41 target; and

  • BofA/Merrill Lynch with a Neutral.

Brean Capital starts Biogen (Nasdaq: BIIB) with a Buy and $184 target. Click Here for more color.

For daily real-time New Coverage go to http://www.streetinsider.com/New+Coverage

Visit our new Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Special Reports

Related Entities

Credit Suisse, UBS, Citi, Merrill Lynch, Robert W Baird, Bank of America, Lazard, RBC Capital, Barclays, Susquehanna International Group of Companies, Notable Analyst Rating Changes, Wells Fargo

Add Your Comment